Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $301,381,000 | $268,203,000 | $282,037,000 | $288,720,000 |
| % Growth | 12.4% | -4.9% | -2.3% | – |
| Cost of Goods Sold | $123,531,000 | $104,371,000 | $106,050,000 | $108,337,000 |
| Gross Profit | $177,850,000 | $163,832,000 | $175,987,000 | $180,383,000 |
| % Margin | 59% | 61.1% | 62.4% | 62.5% |
| R&D Expenses | $20,727,000 | $19,366,000 | $20,251,000 | $22,876,000 |
| G&A Expenses | $84,648,000 | $82,318,000 | $78,376,000 | $74,492,000 |
| SG&A Expenses | $134,104,000 | $133,722,000 | $135,770,000 | $136,047,000 |
| Sales & Mktg Exp. | $49,456,000 | $51,404,000 | $57,394,000 | $61,555,000 |
| Other Operating Expenses | $322,000 | -$136,000 | $335,000 | $170,000 |
| Operating Expenses | $154,831,000 | $153,088,000 | $156,021,000 | $158,923,000 |
| Operating Income | $23,018,000 | $10,743,000 | $19,965,000 | $21,460,000 |
| % Margin | 7.6% | 4% | 7.1% | 7.4% |
| Other Income/Exp. Net | $4,175,000 | $8,827,000 | $1,133,000 | $8,637,000 |
| Pre-Tax Income | $27,193,000 | $19,570,000 | $21,098,000 | $30,311,000 |
| Tax Expense | $8,196,000 | $6,448,000 | $7,782,000 | $8,423,000 |
| Net Income | $18,997,000 | $13,122,000 | $13,316,000 | $20,172,000 |
| % Margin | 6.3% | 4.9% | 4.7% | 7% |
| EPS | 231.72 | 161.12 | 166.83 | 252.73 |
| % Growth | 43.8% | -3.4% | -34% | – |
| EPS Diluted | 231.42 | 160.93 | 166.63 | 252.44 |
| Weighted Avg Shares Out | 81,982 | 81,444 | 79,816 | 79,815 |
| Weighted Avg Shares Out Dil | 82,088 | 81,538 | 79,907 | 79,900 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,592,000 | $1,338,000 | $1,690,000 | $3,769,000 |
| Interest Expense | $169,000 | $170,000 | $156,000 | $118,000 |
| Depreciation & Amortization | $24,648,000 | $23,074,000 | $22,041,000 | $16,695,000 |
| EBITDA | $54,315,000 | $44,642,000 | $45,173,000 | $41,824,000 |
| % Margin | 18% | 16.6% | 16% | 14.5% |